Shares of ProNAi Therapeutics Inc. (NASDAQ:DNAI) were up 6% during trading on Monday . The company traded as high as $2.15 and last traded at $2.13, with a volume of 1,182,737 shares trading hands. The stock had previously closed at $2.01.

A number of analysts have recently commented on DNAI shares. Jefferies Group reissued a “buy” rating on shares of ProNAi Therapeutics in a research note on Sunday, May 29th. Zacks Investment Research lowered ProNAi Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Wedbush lowered ProNAi Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Monday, June 6th. Finally, SunTrust Banks Inc. lowered ProNAi Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $25.00 to $4.00 in a research note on Monday, June 6th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $17.35.

The firm has a 50 day moving average price of $2.64 and a 200 day moving average price of $6.19. The firm’s market capitalization is $65.48 million.

ProNAi Therapeutics (NASDAQ:DNAI) last released its earnings results on Tuesday, May 10th. The company reported ($0.35) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.07. Analysts anticipate that ProNAi Therapeutics Inc. will post ($1.33) EPS for the current year.

An institutional investor recently bought a new position in ProNAi Therapeutics stock. Jennison Associates bought a new stake in shares of ProNAi Therapeutics Inc. (NASDAQ:DNAI) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 150,381 shares of the company’s stock, valued at approximately $3,086,000. Jennison Associates owned about 0.50% of ProNAi Therapeutics at the end of the most recent quarter.

ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.